Arcturus Therapeutics announced the appointment of Steve Hughes, M.D., as Chief Development Officer, effective January 2, 2020. Dr. Hughes brings over twenty years of clinical development experience in the fields of rare diseases, cardiovascular disease, and oncology. His most recent successes include RNA therapeutic approvals at Ionis Pharmaceuticals for the treatment of rare diseases including transthyretin-mediated amyloidosis (TEGSEDI®), familial chylomicronemia syndrome (WAYLIVRA®) and spinal muscular atrophy (SPINRAZA®). Dr. Hughes will provide seasoned leadership and direction to Clinical Operations, Clinical Affairs, Clinical Sciences, Data Management/Biometrics, and Drug Safety. As an Officer of the Company, he will serve on the Senior Management Team. His initial focus will be on ARCT-810, a treatment for ornithine transcarbamylase (OTC) deficiency, as it advances into human trials. Most recently he served as the Chief Medical Officer of Organovo where he led the non-clinical and clinical development teams developing bioprinted tissues for treatment of hepatic and renal diseases.